

# Tadamitsu Kishimoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6157885/publications.pdf>

Version: 2024-02-01

165  
papers

42,823  
citations

5261

83  
h-index

7340

152  
g-index

167  
all docs

167  
docs citations

167  
times ranked

35127  
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014, 6, a016295-a016295.	2.3	2,943
2	Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 1986, 324, 73-76.	13.7	2,028
3	Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 1994, 368, 339-342.	13.7	1,680
4	Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 1988, 332, 83-85.	13.7	1,631
5	gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES. Annual Review of Immunology, 1997, 15, 797-819.	9.5	1,394
6	Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 1989, 58, 573-581.	13.5	1,387
7	Cytokine signal transduction. Cell, 1994, 76, 253-262.	13.5	1,318
8	Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell, 1990, 63, 1149-1157.	13.5	1,293
9	IL-6: Regulator of Treg/Th17 balance. European Journal of Immunology, 2010, 40, 1830-1835.	1.6	1,291
10	Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997, 387, 924-929.	13.7	1,224
11	Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB Journal, 1990, 4, 2860-2867.	0.2	1,204
12	Interleukin-6 in Biology and Medicine. Advances in Immunology, 1993, 54, 1-78.	1.1	1,191
13	Biological and clinical aspects of interleukin 6. Trends in Immunology, 1990, 11, 443-449.	7.5	1,038
14	INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology. Annual Review of Immunology, 2005, 23, 1-21.	9.5	882
15	Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology, 1988, 18, 1797-1802.	1.6	790
16	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2004, 50, 1761-1769.	6.7	751
17	Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet, The, 2008, 371, 998-1006.	6.3	734
18	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases, 2007, 66, 1162-1167.	0.5	674

#	ARTICLE	IF	CITATIONS
19	Humanized anti-IL-6 receptor antibody treatment of multicentric Castleman disease. <i>Blood</i> , 2005, 106, 2627-2632.	0.6	670
20	IL-6: from its discovery to clinical applications. <i>International Immunology</i> , 2010, 22, 347-352.	1.8	664
21	A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. <i>Gastroenterology</i> , 2004, 126, 989-996.	0.6	600
22	Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19961-19966.	3.3	582
23	Targeting Interleukin-6 Signaling in Clinic. <i>Immunity</i> , 2019, 50, 1007-1023.	6.6	570
24	Interleukin 6: from bench to bedside. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 619-626.	3.2	536
25	Immunotherapeutic implications of IL-6 blockade for cytokine storm. <i>Immunotherapy</i> , 2016, 8, 959-970.	1.0	521
26	IL-6 and NF-IL6 in Acute-Phase Response and Viral Infection. <i>Immunological Reviews</i> , 1992, 127, 25-50.	2.8	496
27	Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 88-95.	3.1	465
28	Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9721-9726.	3.3	458
29	Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. <i>FEBS Letters</i> , 1988, 232, 347-350.	1.3	398
30	Interleukin-6: discovery of a pleiotropic cytokine. <i>Arthritis Research and Therapy</i> , 2006, 8, S2.	1.6	396
31	Induction of rat acute-phase proteins by interleukin 6 in vivo. <i>European Journal of Immunology</i> , 1988, 18, 717-721.	1.6	394
32	Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. <i>Blood</i> , 2000, 95, 56-61.	0.6	381
33	Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. <i>FEBS Letters</i> , 1989, 250, 607-610.	1.3	377
34	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020, 16, 335-345.	3.5	369
35	Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. <i>Journal of Experimental Medicine</i> , 2009, 206, 2027-2035.	4.2	368
36	Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1521-1529.	6.7	359

#	ARTICLE	IF	CITATIONS
37	Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. <i>European Journal of Immunology</i> , 1988, 18, 951-956.	1.6	338
38	Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 818-825.	6.7	336
39	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009, 19, 12-19.	0.9	312
40	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9041-9046.	3.3	308
41	Prevention of autoimmune insulinitis by expression of I $\alpha$ E molecules in NOD mice. <i>Nature</i> , 1987, 328, 432-434.	13.7	305
42	Recombinant human B cell stimulatory factor 2 (BSF-2/IFN- $\gamma$ 2) regulates $\beta$ -fibrinogen and albumin mRNA levels in Fao-9 cells. <i>FEBS Letters</i> , 1987, 221, 18-22.	1.3	296
43	The Biology and Medical Implications of Interleukin-6. <i>Cancer Immunology Research</i> , 2014, 2, 288-294.	1.6	283
44	Action of recombinant human interleukin 6, interleukin 1 $\beta$ and tumor necrosis factor $\alpha$ on the mRNA induction of acute-phase proteins. <i>European Journal of Immunology</i> , 1988, 18, 739-746.	1.6	255
45	Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 2117-2121.	6.7	254
46	Therapeutic Targeting of the Interleukin-6 Receptor. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 199-219.	4.2	240
47	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009, 19, 12-19.	0.9	228
48	Cytokine receptors and signal transduction. <i>FASEB Journal</i> , 1992, 6, 3387-3396.	0.2	225
49	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
50	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22351-22356.	3.3	215
51	Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. <i>Arthritis and Rheumatism</i> , 2008, 58, 3710-3719.	6.7	211
52	Postnatally Induced Inactivation of gp130 in Mice Results in Neurological, Cardiac, Hematopoietic, Immunological, Hepatic, and Pulmonary Defects. <i>Journal of Experimental Medicine</i> , 1998, 188, 1955-1965.	4.2	208
53	Direct evidence for the contribution of the unique I-ANOD to the development of insulinitis in non-obese diabetic mice. <i>Nature</i> , 1990, 345, 722-724.	13.7	205
54	Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. <i>International Journal of Biological Sciences</i> , 2012, 8, 1227-1236.	2.6	200

#	ARTICLE	IF	CITATIONS
55	Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. <i>European Journal of Immunology</i> , 1993, 23, 820-824.	1.6	195
56	Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. <i>Arthritis and Rheumatism</i> , 1999, 42, 1635-1643.	6.7	195
57	Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. <i>FEBS Journal</i> , 1988, 173, 287-293.	0.2	183
58	Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9409-9414.	3.3	179
59	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. <i>Rheumatology</i> , 2010, 49, 2408-2412.	0.9	177
60	Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2677-86.	3.3	174
61	Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells. <i>Blood</i> , 1998, 91, 2969-2976.	0.6	167
62	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 535-551.	1.3	166
63	Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3. <i>Biochemical and Biophysical Research Communications</i> , 1997, 237, 79-83.	1.0	164
64	Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1). <i>FEBS Letters</i> , 1988, 234, 17-21.	1.3	158
65	The roles of aryl hydrocarbon receptor in immune responses. <i>International Immunology</i> , 2013, 25, 335-343.	1.8	157
66	Therapeutic uses of anti-interleukin-6 receptor antibody. <i>International Immunology</i> , 2015, 27, 21-29.	1.8	146
67	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. <i>Seminars in Immunology</i> , 2014, 26, 88-96.	2.7	144
68	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3528.	1.8	143
69	Regulation of IL-6 in Immunity and Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 941, 79-88.	0.8	135
70	TLR4-induced NF- $\kappa$ B and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. <i>Nucleic Acids Research</i> , 2017, 45, 2687-2703.	6.5	129
71	Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. <i>Arthritis and Rheumatism</i> , 2008, 58, 754-763.	6.7	123
72	ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE. <i>Cytokine</i> , 2002, 20, 304-311.	1.4	118

#	ARTICLE	IF	CITATIONS
73	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1116-1123.	3.2	116
74	Therapeutic effect of tocilizumab on two patients with polymyositis. <i>Rheumatology</i> , 2011, 50, 1344-1346.	0.9	115
75	Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma. <i>American Journal of Pathology</i> , 2012, 180, 165-176.	1.9	115
76	Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11964-11969.	3.3	115
77	Aryl Hydrocarbon Receptor and Kynurenine: Recent Advances in Autoimmune Disease Research. <i>Frontiers in Immunology</i> , 2014, 5, 551.	2.2	115
78	Historical overview of the interleukin-6 family cytokine. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	115
79	Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14222-14227.	3.3	111
80	Studies on the structure and regulation of the human hepatic interleukin-6 receptor. <i>FEBS Journal</i> , 1990, 190, 79-83.	0.2	103
81	Effects of metabolite binding to ribulosebisphosphate carboxylase on the activity of the Calvin photosynthesis cycle. <i>FEBS Journal</i> , 1988, 177, 351-355.	0.2	102
82	B-cell stimulatory factors (BSFs): Molecular structure, biological function, and regulation of expression. <i>Journal of Clinical Immunology</i> , 1987, 7, 343-355.	2.0	99
83	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	0.9	97
84	Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. <i>European Journal of Immunology</i> , 1990, 20, 1747-1753.	1.6	89
85	Aryl hydrocarbon receptor negatively regulates LPS-induced IL-6 production through suppression of histamine production in macrophages. <i>International Immunology</i> , 2011, 23, 637-645.	1.8	81
86	Structure-function analysis of human interleukin-6. <i>FEBS Letters</i> , 1990, 262, 323-326.	1.3	79
87	Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. <i>Journal of Experimental Medicine</i> , 2016, 213, 605-619.	4.2	76
88	The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. <i>International Immunology</i> , 2015, 27, 405-415.	1.8	71
89	Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis. , 2011, 52, 3264.		70
90	Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1762-1764.	6.7	69

#	ARTICLE	IF	CITATIONS
91	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001, 98, 3042-3049.	0.6	68
92	A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders. <i>Trends in Molecular Medicine</i> , 2017, 23, 348-361.	3.5	65
93	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	0.9	64
94	The soluble form of the IL-6 receptor (sIL-6R) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R-induced AIDS-KS cell growth. <i>International Immunology</i> , 1996, 8, 595-602.	1.8	52
95	Aryl hydrocarbon receptor and experimental autoimmune arthritis. <i>Seminars in Immunopathology</i> , 2013, 35, 637-644.	2.8	51
96	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. <i>Annual Review of Immunology</i> , 2022, 40, 323-348.	9.5	50
97	Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1214-E1220.	3.3	49
98	Arid5a exacerbates IFN- $\gamma$ -mediated septic shock by stabilizing T-bet mRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11543-11548.	3.3	46
99	Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11802-11807.	3.3	46
100	Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 627-628.	0.5	41
101	Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. <i>Trends in Immunology</i> , 2020, 41, 255-268.	2.9	41
102	Differentiation of B cell progenitors in vitro: Generation of surface IgM+ B cells, including Ly-1 B cells, from Thy-1 <sup>hi</sup> asialoGM1+ cells in newborn liver. <i>European Journal of Immunology</i> , 1987, 17, 1769-1774.	1.6	40
103	Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 387-397.	1.2	39
104	Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis. <i>Journal of Experimental Pharmacology</i> , 2015, 7, 29.	1.5	39
105	Augmentation of haptoglobin production in Hep3B cell line by a nuclear factor NF-IL6. <i>FEBS Letters</i> , 1991, 291, 58-62.	1.3	38
106	Favorable Responses to Tocilizumab in Two Patients With Cancer-Related Cachexia. <i>Journal of Pain and Symptom Management</i> , 2013, 46, e9-e13.	0.6	36
107	Arid5a stabilizes OX40 mRNA in murine CD4 <sup>+</sup> T cells by recognizing a stem-loop structure in its 3'UTR. <i>European Journal of Immunology</i> , 2018, 48, 593-604.	1.6	35
108	BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. <i>American Journal of Hematology</i> , 1989, 31, 258-262.	2.0	34

#	ARTICLE	IF	CITATIONS
109	The <i>in vivo</i> Anti-tumor Effect of Human Recombinant Interleukin-6. Japanese Journal of Cancer Research, 1990, 81, 1032-1038.	1.7	33
110	Arid5a Regulation and the Roles of Arid5a in the Inflammatory Response and Disease. Frontiers in Immunology, 2019, 10, 2790.	2.2	29
111	CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. European Journal of Immunology, 1988, 18, 451-457.	1.6	28
112	A new interleukin with pleiotropic activities. BioEssays, 1988, 9, 11-15.	1.2	27
113	Identification of intrathymic T progenitor cells by expression of Thy-1, IL 2 receptor and CD3. European Journal of Immunology, 1987, 17, 1567-1571.	1.6	26
114	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern Rheumatology, 2015, 25, 134-137.	0.9	26
115	Noncanonical STAT1 phosphorylation expands its transcriptional activity into promoting LPS-induced IL-6 and IL-12p40 production. Science Signaling, 2020, 13, .	1.6	26
116	Interleukin 6 and its receptor in the immune response and hematopoiesis. International Journal of Cell Cloning, 1990, 8, 155-167.	1.6	25
117	Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation. FEBS Letters, 1990, 263, 349-354.	1.3	24
118	Chemical modification and 1H-NMR studies on the receptor-binding region of human interleukin 6. FEBS Journal, 1991, 196, 377-384.	0.2	24
119	Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon <i>via</i> suppression of the TRIF/IRF3 pathway. International Immunology, 2016, 28, 307-315.	1.8	24
120	Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
121	Cell-free-synthesized interleukin-6 (BSF-2/IFN-beta2) exhibits hepatocyte-stimulating activity. FEBS Journal, 1988, 175, 181-186.	0.2	22
122	Feedback regulation of Arid5a and Ppar- $\gamma$ 2 maintains adipose tissue homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15128-15133.	3.3	22
123	Current Concepts of B Cell Modulation. International Reviews of Immunology, 1989, 5, 97-109.	1.5	17
124	Arid5a-deficient mice are highly resistant to bleomycin-induced lung injury. International Immunology, 2017, 29, 79-85.	1.8	17
125	IL-6: from arthritis to CAR-T-cell therapy and COVID-19. International Immunology, 2021, 33, 515-519.	1.8	17
126	Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10625-10630.	3.3	16



#	ARTICLE	IF	CITATIONS
127	The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway. <i>Cancer Letters</i> , 2021, 520, 295-306.	3.2	16
128	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	0.9	15
129	Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression. <i>Cancer Immunology Research</i> , 2021, 9, 862-876.	1.6	15
130	Site-specific mutagenesis of human interleukin-6 and its biological activity. <i>FEBS Letters</i> , 1991, 281, 167-169.	1.3	14
131	Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells. <i>Experimental Dermatology</i> , 2015, 24, 864-871.	1.4	14
132	A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression. <i>Current Pharmaceutical Design</i> , 2018, 24, 1766-1771.	0.9	14
133	IL-6: A New Era for the Treatment of Autoimmune Inflammatory Diseases. , 2015, , 131-147.		14
134	Roles of RNA-binding proteins in immune diseases and cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 310-324.	4.3	14
135	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 054-065.	1.5	13
136	Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. <i>International Journal of Cardiology</i> , 2015, 187, 319-321.	0.8	13
137	Identification of alternative splicing form of Stat2. <i>FEBS Letters</i> , 1996, 381, 191-194.	1.3	12
138	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. <i>Modern Rheumatology</i> , 2013, , 1.	0.9	12
139	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	0.9	12
140	Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia. <i>International Journal of Hematology</i> , 2004, 80, 246-249.	0.7	10
141	Expression of aryl hydrocarbon receptor, inflammatory cytokines, and incidence of rheumatoid arthritis in Vietnamese dioxin-exposed people. <i>Journal of Immunotoxicology</i> , 2017, 14, 196-203.	0.9	10
142	Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1941-1950.	1.9	10
143	Structure and Function of Fc $\gamma$ Receptor II (Fc $\gamma$ RII/CD23): A Point of Contact Between the Effector Phase of Allergy and B Cell Differentiation. <i>Novartis Foundation Symposium</i> , 1989, 147, 23-35.	1.2	10
144	Current status and prospects of IL-6-targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	1.3	10

#	ARTICLE	IF	CITATIONS
145	CD5: A New Partner for IL-6. <i>Immunity</i> , 2016, 44, 720-722.	6.6	9
146	Discovery of IL-6 and Development of Anti-IL-6R Antibody. <i>Keio Journal of Medicine</i> , 2019, 68, 96-96.	0.5	7
147	Recent Advances in the Role of Arid5a in Immune Diseases and Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 827611.	2.2	6
148	Identification of a Transcriptional Regulatory Factor for Human Aromatase Cytochrome <i>cyp19a1</i> Gene Expression as Nuclear Factor Interleukin-6 (NF-IL6), a Member of the CCAAT/Enhancer-Binding Protein Family. <i>FEBS Journal</i> , 1995, 231, 292-299.	0.2	5
149	Interleukin 6. , 2014, , 1-8.		4
150	V-ABL does not abolish IL-6 requirement by murine plasmacytoma cells. <i>International Journal of Cancer</i> , 1991, 48, 234-238.	2.3	3
151	Molecular structure of interleukin 6 receptor.. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 1988, 64, 209-211.	1.6	2
152	Hairy Root Cultures of <i>Eurycoma longifolia</i> and Production of Anti-inflammatory 9-Methoxycanthin-6-one. <i>Natural Product Communications</i> , 2018, 13, 1934578X1801300.	0.2	2
153	B cell stimulatory factor 2(BSF2/IL-6) and rheumatoid arthritis.. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 1987, 63, 281-283.	1.6	1
154	Therapeutic outlook for Castleman's disease: prospects for the next decade. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 633-640.	0.5	1
155	Implications of IL-6 Targeting Therapy for Sepsis. <i>Immunotherapy (Los Angeles, Calif )</i> , 2017, 03, .	0.1	1
156	(1) REGULATION OF THE IgE ANTIBODY RESPONSE. <i>The Journal of the Japanese Society of Internal Medicine</i> , 1981, 70, 1490-1493.	0.0	0
157	Regulation of the IgE antibody response.. <i>Japanese Journal of Medicine</i> , 1982, 21, 57-59.	0.1	0
158	IgM Induction in Murine B Hybridomas with Ia-Restricted T Cell Clones: A Monoclonal Model for T and B Cell Interactions in Antibody Response. <i>Microbiology and Immunology</i> , 1985, 29, 993-1003.	0.7	0
159	Regulation of B lymphocyte differentiation.. <i>Japanese Journal of Medicine</i> , 1985, 24, 186-187.	0.1	0
160	Transfer of the Ea gene into NOD mice prevents the development of autoimmune insulinitis.. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 1987, 63, 155-157.	1.6	0
161	Interleukin 6 (BSF2/IL-6) is an autocrine growth factor for human multiple myelomas.. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 1988, 64, 68-71.	1.6	0
162	Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2105040118.	3.3	0

#	ARTICLE	IF	CITATIONS
163	Interleukin 6. , 2016, , 686-692.		0
164	Epithelial miRâ€215 negatively modulates Th17â€dominant inflammation by inhibiting CXCL12 production in the small intestine. Genes To Cells, 2022, 27, 243-253.	0.5	0
165	The emerging role of Arid5a in cancer: A new target for tumors. Genes and Diseases, 2022, , .	1.5	0